How does 6Y1's PS Ratio compare to its peers?

6Y1 is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2.1x).

How does 6Y1's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

6Y1 is expensive based on its Price-To-Sales Ratio (4.4x) compared to the European Medical Equipment industry average (3.6x).

What is 6Y1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6Y1 is good value based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

What is the Fair Price of 6Y1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 6Y1's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

Integrum (DB:6Y1) - Stock Price, News & Analysis

6Y1 Stock Overview

Researches, develops, and sells various systems for bone-anchored prostheses.

About the company

6Y1 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 87.23% per year

Earnings have grown 23.4% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€479M)

Integrum AB (publ) Competitors

aap Implantate

XTRA:AAQ1

€21.9m

PULSION Medical Systems

MUN:PUS

€127.8m

Geratherm Medical

XTRA:GME

€17.4m

Audientes

DB:AUG

€6.9m

Price History & Performance

Summary of all time highs, changes and price drops for Integrum
Historical stock prices
Current Share Price	SEK 2.14
52 Week High	SEK 5.30
52 Week Low	SEK 2.12
Beta	1.71
11 Month Change	-4.04%
3 Month Change	-48.43%
1 Year Change	-10.27%
33 Year Change	-76.69%
5 Year Change	n/a
Change since IPO	-52.23%

Recent updates

Shareholder Returns

	6Y1	DE Medical Equipment	DE Market
7D	-3.2%	-3.6%	-2.2%
1Y	-10.3%	-3.5%	13.3%

Return vs Industry: 6Y1 underperformed the German Medical Equipment industry which returned -2.7% over the past year.

Return vs Market: 6Y1 underperformed the German Market which returned 13.6% over the past year.

Price Volatility

Is 6Y1's price volatile compared to industry and market?
6Y1 volatility
6Y1 Average Weekly Movement	11.6%
Medical Equipment Industry Average Movement	5.3%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6Y1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6Y1's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1962	36	Scott Flora	www.integrum.se

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads.

Integrum AB (publ) Fundamentals Summary

How do Integrum's earnings and revenue compare to its market cap?
6Y1 fundamental statistics
Market cap	€41.07m
Earnings (TTM)	-€204.11k
Revenue (TTM)	€9.39m

4.4x

P/S Ratio

-201.2x

P/E Ratio

Is 6Y1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6Y1 income statement (TTM)
Revenue	SEK 109.51m
Cost of Revenue	SEK 20.36m
Gross Profit	SEK 89.15m
Other Expenses	SEK 91.53m
Earnings	-SEK 2.38m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

Dec 04, 2024

Earnings per share (EPS)	-0.12
Gross Margin	81.41%
Net Profit Margin	-2.17%
Debt/Equity Ratio	0%

How did 6Y1 perform over the long term?

See historical performance and comparison

6Y1 Stock Overview

Rewards

Risk Analysis

Integrum AB (publ) Competitors

XTRA:AAQ1

€21.9m

MUN:PUS

€127.8m

XTRA:GME

€17.4m

DB:AUG

€6.9m

Price History & Performance

Recent News & Updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

New major risk - Share price stability

Full year 2023 earnings released

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System